Introduction
Int ravenous (IV) insulin infusion therapy has a long history of use in the management of hyperglycemia during the treatment of diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state, and labor and delivery, exhibiting a favorable safety and efficacy profile compared to subcutaneous insulin therapy.
1,2
A reduction of mortality and morbidities during the utilization of intravenous insulin infusion among cardiac surgery patients in Portland, Oregon, and critically ill patients in the surgical intensive care unit (SICU) in Leuven, Belgium, has led to an explosion of interest in this method of delivery of insulin therapy. [3] [4] [5] [6] [7] [8] In recent randomized controlled studies targeting blood glucose (BG) 80-110 mg/dl, however, the mortality rate was not reduced. [9] [10] [11] [12] Recognition of hypoglycemia as a complication of therapy without an apparent outcome advantage led to the closure of two randomized trials of IV insulin therapy. [10] [11] [12] The relationship between hypoglycemia and adverse outcomes has not been fully defined. Among critically ill patients and hospitalized patients in general, hypoglycemia has been shown to be associated with increased mortality. Hypoglycemia simply may be a marker of clinical severity or the consequence of comorbidities. [13] [14] [15] However, cardiac arrest, fatality, and other morbidities have been attributed to regimens that attempt attainment of strict glycemic control. [16] [17] [18] A recent case control study suggests that severe hypoglycemia is an independent predictor of mortality in the critical care setting. 19 The possibility cannot be discounted that even mild hypoglycemia is detrimental to the well-being of patients from selected populations. Sympathetic and other counterregulatory activation is likely to occur as BG approaches 70-72 mg/dl. 20 Among patients having acute myocardial infarction or left ventricular failure, observational studies suggest that a J-shaped relationship may exist between glucose control and mortality. [21] [22] [23] [24] Undeniably, differences dependent on the source of blood and variability of measurement of blood glucose are limiting factors that restrict our ability to achieve target range control. [25] [26] [27] [28] [29] [30] [31] [32] [33] For different conditions, such as DKA or hyperglycemic hyperosmolar state, 34 the target glucose range may differ from that advocated for the surgical ICU. 35 The algorithms available to an institution may perform optimally only for restricted populations or specific target ranges of BG.
36 If the desired range of glycemic control could be achieved through the use of carefully engineered insulin infusion algorithms without fear of hypoglycemia, and with adaptability of target range to various populations, researchers might safely investigate glycemic targets necessary for the attainment of specific outcomes among critically ill patients and caregivers might approach the demonstrably optimal target ranges with confidence. The nursing burden may be reduced. Use might be extended safely to general wards. Applicability of the design principles may extend to continuous subcutaneous insulin therapy in the ambulatory setting. For these reasons, engineering of an insulin algorithm to achieve a given target range that avoids hypoglycemia is a high priority. The purpose of this article is to describe the evolution of the algorithm "I, Pancreas."
Background
The maintenance rate (MR) seeking or "MR" algorithm is a family of functions giving the insulin infusion rate (IR) as a function of current BG (BG current ) and the maintenance rate of insulin infusion, such that each function differs from the other members of the family only according to MR, multiplier, or column assignment when expressed as a function of BG. 37, 38 In one published graphical display, curves differ according to multiplier, 39 whereas in another differ according to column assignment. 36 If the parameters of the algorithm, such as target BG or ideal rate of change at given BG, were revised to match the needs of a different population, then the algorithm would generate a new family of functions.
After each iteration, an MR algorithm assigns the insulin infusion rate in two steps. Using the previous insulin infusion rate (IR previous ) or previous multiplier, the previous blood glucose (BG previous ), the BG current , and the time between tests (∆ time previous ), the algorithm first determines the next MR, the next column assignment, or the next multiplier. Using the distance from target of BG current , the second step of the algorithm defines the IR for the next iteration of the algorithm (IR next ). The IR is an increasing function of BG. At any given BG the rate of change of IR with respect to BG, or d(IR)/d(BG), is an increasing function of MR. The algorithm also states the time for the next blood glucose measurement.
The principal input and output are shared by all available algorithms: BG current , BG previous , IR previous , current test time (test time current ), and previous test time (test time previous ). The use of intermediary variables may make the logic of the algorithm more transparent. In the first step, an MR algorithm is likely to compute the previous rate of descent of blood glucose (ROD previous ) or the change or fractional change of blood glucose, which are functions of input data. In the second step, again intermediary variables may be expressed as functions of BG current , such as the ideal change or rate of change of blood glucose for the next iteration. Unless other features are added to allow user input, the algorithm response to changes of carbohydrate exposure or other patient conditions is reactive, but the design allows rediscovery of MR with changing conditions.
Three Predecessor Tabular Columnar Protocols
The Markovitz algorithm was designed to seek the MR and, in assigning IR, to make corrections commensurate to the MR. 40 A strategy from ambulatory medicine requires use of the "insulin sensitivity factor" (ISF) and total daily dose of insulin (TDDI) for correction dosing during hyperglycemia, where the ISF is computed to be equal to one of the following : 1500/TDDI = drop of BG /1 unit of insulin 1800/TDDI = drop of BG /1 unit of insulin 1720/TDDI = drop of BG /1 unit of insulin The parameter 1500, 1800, or 1720 in milligrams per deciliter might be called the glucose per daily dose of insulin exogenously mediated (G-per-DIEM) parameter. In order to compute the correction dose of short-or rapid-acting subcutaneous insulin, the rule holds that in addition to the TDDI, the correction dose of short-or rapid-acting insulin equals (BG current -BG target)/ISF. Problems with the method that must be acknowledged are stated as follows: (a) saturation behavior at higher BG and higher insulin doses is not acknowledged under the rule, (b) the true value of the parameter "1800 mg/dl" is not well established for various populations or patient conditions, (c) the time course of BG response is poorly documented, and (d) the true needed TDDI may be a "moving target."
The rule can be converted to a rule for IV insulin therapy that apportions the infusion rate during hyperglycemia between maintenance rate and correction rate (CR). for correction of hyperglycemia was tolerated perhaps in part because MR had not yet been assigned at its true value. During hyperglycemia, above upper target BG upper target 105 mg/dl, full correction was attempted within the time frame of every iteration:
Using these concepts, the Markovitz tabular dose-defining, column-based algorithm was created for implementation by nurses, assigning the threshold for column adjustment (BG critical high ) to be 200 mg/dl, assigning the target for correction rates of insulin infusion (BG upper target ) to be 180 mg/dl, and using as G-per-DIEM the value of 1500 mg/dl. A lower target BG (BG lower target ) of 120 mg/dl was assigned. Several MR values were selected typical for the population, specifically 1, 1.5, 2, 3, and 4 units per hour. The recommended IR values ( = MR + CR values) were computed from MR values and were rounded off for display in the cells of the table. Each column was identified with an MR. Rows were displayed in order of ascending BG. Arbitrary column-changing rules were applied reactive to rate of change of blood glucose, and for BG below BG lower target or prolonged time within target, a column down-changing rule was applied.
The protocol targeted full correction to BG upper target within the time frame of every iteration, be it 1 or 2 hours. During hyperglycemia, full correction was not achieved consistently by the next test time, despite delivery of the entire correction insulin dose by IV infusion. Alternatively, overshoot occurred. Below BG upper target , because the algorithm lacked any specific theory for management on the euglycemic range, decrements of IR were arbitrary.
The Clinical Management Committee at the University of North Carolina in 2002 requested development of an IV insulin protocol to facilitate and standardize the management of intravenous insulin infusion therapy. Pilot sites included the cardiothoracic ICU and the operating room. The BG upper target was 150 mg/dl, BG lower target was 100 mg/dl, and G-per-DIEM was 1800 mg/dl. The MR values selected to be typical for the population were 1, 1.5, 2, 3, 4, and 6 units per hour, as shown in the second appendix published by Bode, Braithwaite, et al. 2 The surgical trauma service at the University of North Carolina requested an IV insulin protocol that would safely target the range identified with improved outcomes in the SICU. 8 The pilot population would be trauma service ICU patients. The BG upper target was 110 mg/dl, BG lower target was 80 mg/dl, and G-per-DIEM was 1800 mg/dl. The MR values selected to be typical for the population were 1, 2, 3, 4, 6, and 8 units per hour. The initial MR (MR initial ) was 2 units/h. During hyperglycemia, column up-titration was required if ROD previous for the preceding 2 hours failed to reach ROD @BGcritical high or 30 mg/dl per hour for BG current ≥ BG critical high , or 180 mg/dl. The rule To minimize hypoglycemia, a permissive strategy for the euglycemic ascent of BG current to BG true target was devised. On the euglycemic range, IR next would be exponentially dependent on the fractional completeness of the ascent of BG (FCABG) from 70 to 105 mg/dl, defining a range between hypoglycemia and the true target blood glucose (BG true target ), assigning IR = 0.1 units/h for BG 70 mg/dl and IR = MR at BG true target . An implicit assumption was that the maximum rate of ascent of blood glucose (ROA max ) for the population at blood glucose 70 mg/dl during negligible insulin infusion might be about 17.5 mg/dl per hour. The BG true target was 105 mg/dl, and FCABG was given by FCABG = (BG current -70 mg/dl)/(BG true target -70 mg/dl).
For BG current between 70 and 105 mg/dl, the IR next was given by IR next = IR @BG70 * e ln(MR/IR @BG70 ) * FCABG Between BG 105 and 109 mg/dl, IR next = MR. Use of the algorithm spread quickly from the pilot population to other SICU patients and to burn unit patients. 41, 42 The University of North Carolina now had two tabular columnar paper protocols for IV insulin infusion in critical care units. These infusion protocols are not applicable for all patients, such as those having DKA or a hyperglycemic hyperosmolar state, pediatric patients, or special situations requiring a revision of parameters, including glycemic targets. 36 Another problem was the cost of ICU care and the potential burden on the nursing staff, preventing extension to general wards. In addition, problems that required resolution included glycemic variability within the treatment course, failure of the protocol targeting BG 80-110 mg/dl to preserve target range control even half of the time, and occasional hypoglycemia. At a given column assignment, the column-change rules that were used to define the MR required conservative holding periods at a given column assignment that might span many hours before column Institutional review board approval was obtained for a waiver of consent to review data from cases treated under the historical protocol. Historical data points from that series were used in which blood glucose determinations were plasma correlated. User-definable parameters were retained that are implicit in the management of hyperglycemia under the predecessor paper protocol, 41 appropriate to surgical ICU patients (BG true target = 105 mg/dl, BG upper target = 110 mg/dl, BG critical high = 180 mg/dl, ROD @BGcritical high = 30 mg/dl per hour, MR initial = 2 units/h), with additional provisions that the maximum assignable value for ideal rate of descent of BG for the next iteration (ROD ideal,next,max ) = 70 mg/dl per hour, IR max = 36 units/h, and rehydration time = 0. The G-per-DIEM parameter for the population, although not confirmed by experimentation and not user assignable, for purposes of testing the algorithm was estimated as G-per-DIEM = 1800 mg/dl, as in the predecessor paper protocol. 
Comparison of IR

User-defined parameters
Computerization is expected to show superiority to manual methods, as has been shown in studies from other centers. [43] [44] [45] The immediate research questions were whether assignments of MR could be made by methods that are not arbitrary; whether assignments of the IR and CR, both commensurate to MR, give reasonable values; and whether true maintenance requirements for insulin can be predicted by the computation of MR prior to the attainment of euglycemia. This article presents a simple statement of design elements of the algorithm; then the methods used in feasibility studies that tested the output of the algorithm against historical time points; and finally results of the feasibility studies and an expanded statement on design and theory of the algorithm, followed by discussion and comments on future implementation.
Methods
Feasibility Studies for Computing Maintenance Rate Cross
Step Next Estimate (MR csne ) and MR csne -Dependent IR To prepare for creation of an electronic protocol, we began analyzing the feasibility of computing MR csne as a precedent for computing IR. A formula for MR was derived by rearrangement of the equation for IR, applied to the previous iteration. The computed MR was called the "maintenance rate cross step next estimate."
A tabular paper protocol, the predecessor to the protocol under evaluation, had been used in the treatment of a published series of trauma service patients. 
Ability of MR csne to Estimate MR true
The hypothetical value of MR csne upon entry to a stable interval was compared to the averaged hourly requirement for insulin during the ensuing stable interval. In the formula for MR csne , the last BG ≥110 mg/dl prior to the interval was used as BG previous , and the first BG <110 mg/dl was used as BG current . The time between them (1 or 2 hours) was used as ∆ time previous . Because the algorithm was not applied sequentially during historical treatment courses, not the entire sequence of hyperglycemic iterations but only the terminal hyperglycemic iteration prior to euglycemia was used to compute MR csne . MR csne was compared pair wise to MR true on the subsequent stable interval.
Statistical Analyses
Pearson correlation coefficients were computed. The twosided Wilcoxon signed rank test was used for comparison of units of insulin per hour to test the null hypothesis. Results with P < 0.05 were considered statistically significant.
Proposal for Computerized Algorithm "I, Pancreas"
An expanded theory of an algorithm was developed mathematically, and practical recommendations for computerization were proposed. Figure 1 . When a subgroup of 244 evaluable hyperglycemic historical time points prior to first reaching upper target BG <110 mg/dl was selected, among 20 treatment courses that did reach target and 2 that never reached target, the medians (with interquartile ranges) in insulin units per hour were MR csne 4.24 (3.16-6.97), MR csne -dependent IR next 5.6 (3.9-9.0), and historically assigned IR next 5.0 (3.5-8.0) . Paired data MR csne -dependent IR next and historical IR next differed significantly according to the two-sided Wilcoxon signed rank test (Z = 14.482, P < 0.0001).
Results
Feasibility Studies for
Eighteen treatment courses were identified containing 30 qualifying stable intervals of at least 8 hours of duration, each initiated by the attainment of normoglycemia, following a preceding interval of hyperglycemia. The median (with interquartile ranges) of the mean BG on individual stable intervals was 112.5 mg/dl (106.3-117.6, n = 30 stable intervals). At 30 stable intervals, the medians (and interquartile ranges) in insulin units per hour were MR csne 3.2 (1.5-4.6) and IR mean, stable interval 2.7 (1.2-3.7). Insulin infusion rate as a function of blood glucose at given values of the maintenance rate. After each iteration, the first step of the algorithm is determination of a value for MR, which then becomes a parameter value for the second step of the algorithm. The second step is determination of IR as a function of BG and MR, displayed as a family of iso-MR curves. For computation of the ideal rate of descent of BG for the next iteration (ROD ideal,next ) as a function of BG, the segmented linear method is used. The ROD ideal,next is used as an intermediary variable in the computation of IR. The family of functions created by the algorithm is shown in Figure 3 .
Proposal for Computerized Algorithm "I, Pancreas"
An expanded theory of the algorithm is presented, together with guidelines for nurse implementation, in Table 1 and Appendices 1-3. Guidelines issued by the computerized algorithm for the next BG test time are shown in Appendix 2.
"Opening Screen and Returning Screen"
The nurse will use a computer "opening screen" for the initial input of data. There will be a "returning screen" for use at the time of scheduled retesting of blood glucose. The "returning screen" may also be used between scheduled test times because of hypoglycemia, or perception of risk for hypoglycemia, such that IR and test time reassignment should be considered under the algorithm.
"Opening screen" accepts:
population data, from which glycemic targets are inferred and presented to user "Yes" or "No" answer to question of whether BG current is a posthypoglycemic recheck for IR previous = 0, a "Yes" or "No" answer to question of whether IR previous = 0 for >2 hours After presenting test time next , the "returning screen" asks whether any of the carbohydrate information has changed or is about to change before "test time next." A qualifying reduction of carbohydrate exposure is a sufficient condition to increase the frequency of monitoring to hourly intervals in accordance with Appendix 2. If applicable, the "returning screen" advises reversion from testing at 2-hour intervals to hourly testing. Information about carbohydrate exposure will be used only to set test time next and potentially reduce the insulin rates. Rules for anticipating an increase of insulin according to carbohydrate exposure will not be actuated during piloting.
"Opening screen" and "returning screen" output:
reminder to request "returning screen" for low BG, change of carbohydrate (other than riders), change of insulin in the TPN, or interruption of CVVHD
General Equation of the Algorithm
Under the hypothesis of the algorithm, the equation that follows give the relationship among IR, the instantaneous rate of change of BG, and the biologic parameter MR. The instantaneous rate of change of BG is embedded in the equation as two functions of BG, namely the rate of change of BG from below target (rate of ascent, or ROA) and the rate of change of BG from above target (rate of descent, or ROD), one of which must be zero at every point in time. Using input from data observed over finite intervals in past time, specifically the observed rate of change of BG and the previous IR, the equation gives estimates of MR. Using the distance of BG current from the target to determine the ideal future values of fractional reduction of ROA from ROA max (FRROA) or ROD, the equation, together with an estimate of MR, gives IR next .
In other words, if the IR from past time and ROA or ROD from past time are provided as input, the MR can be estimated. If the FRROA or ROD projected for future time and an estimate of MR are provided as input, an estimate of IR that will achieve the given future FRROA or ROD can be computed.
The overarching design of the algorithm therefore holds that the IR is a function of BG and MR. In the original concept, a linear rule was used during hyperglycemia, such that IR was linearly dependent on the incremental BG elevation above BG upper target and the MR. An exponential rule was used on the euglycemic range, such that IR rose exponentially as a function of the fractional completeness of ascent of BG and MR. The linear rule now will be replaced during hyperglycemia by a bounded exponential rule. The general equation may be expressed more compactly as follows:
where MR is the maintenance rate of insulin infusion, CR is the correction rate of insulin infusion for hyperglycemia, and IR @BG70 is the insulin infusion rate at BG 70 mg/dl.
The modifying language in the equation is explained as follows.
Exponent for MR/IR @BG70 : during euglycemia, when blood glucose is below true target, the power is the fractional completeness of ascent of current BG, between 70 mg/dl and true target (FCABG), which is equivalent to the fractional reduction of the ROA of BG from the maximum rate of ascent (FRROA); whereas at target and above target, the power is 1
Calculation of CR: when blood glucose exceeds target, ROD is observed in past time or a desired value for ROD is applicable to future time, and CR is a linear function of MR and ROD; whereas at target or below target, CR is 0
The biologic value of MR varies with patient condition. At the beginning of each iteration of the algorithm, an estimation of MR appears as an algorithm parameter in the equation that assigns the next infusion rate (IR next ).
Three Special Parameters Discoverable in Nature
We propose that three special parameters are discoverable in nature, for which estimates can be developed from measurements made routinely in the course of patient treatment, without special physiologic studies, and for which population averages might be determined, specifically:
The ROA max is the maximum rate of ascent of BG that can occur spontaneously in the absence of hypoglycemia or a counterregulatory response to hypoglycemia, occurring during negligible insulin infusion at the boundary between euglycemia and hypoglycemia, at BG ~70 mg/dl. Under given conditions of illness, carbohydrate exposure, and concomitant therapies, the ROA max is assumed to be a discoverable patient characteristic, independent of insulin therapy, insulin secretory capacity, or insulin resistance. The ROA max depends on ambient conditions affecting the glucose appearance rate, specifically the rate of carbohydrate exposure and the maximum rate of hepatic glucose output during nonhypoglycemia.
The G-per-DIEM is the insulin-mediated BG disposal per kilogram body weight in response to the total daily dose of exogenously administered insulin, if expressed in grams per kilogram; or, if divided by the total daily dose of insulin and expressed in milligrams per deciliter, the G-per-DIEM is the insulin-mediated drop of BG concentration in response to 1 unit of insulin:
The MR for each treated patient requiring exogenous insulin therapy is defined as the rate of intravenous insulin infusion necessary to preserve euglycemia under ambient conditions. MR is a patient characteristic, having fluctuations of magnitude.
Putative determinants of the values of the special parameters are shown in Table 2 .
(G-per-DIEM)/(total daily dose of insulin) = (drop of BG)/(1 unit insulin) 
Estimation of the Value of MR
In order to compute IR next , it is necessary to assign an estimated value for MR. The method of assignment is stated in .
It is not possible to measure dIR previous /dROA previous .
For clinical application, MR csne will not be used after iterations in which BG previous was below BG true target , but rather a previously assigned MR value will be carried forward. In the presence of hypoglycemic risk factors or after attainment of BG < lower target BG (BG lower target ), an arbitrary reduction of MR will be made. The arbitrary methods used to assign MR when BG previous < BG true target are listed in Appendix 1.
Assignment of IR next
The Figure 3 showing linear method with maximum allowed value).
The linear model has a long history of practical application in subcutaneous insulin therapy in the ambulatory setting (the "rule of 1500" or "rule of 1800"), when BG is not elevated greatly. In reality, however, saturation kinetics exist, such that at extremely high insulin exposure, as the linear rule may require for extremely high BG elevations, a declining incremental response occurs. 46, 47 One way to acknowledge saturation behavior would be to define a bounded relationship between the infusion rate of insulin and ROD. Another way to acknowledge saturation behavior is to posit a maximum value for the ROD ideal,next as a function of BG.
The linear method used to compute ROD ideal,next in the feasibility studies will be replaced by a method that creates a horizontal asymptote for ROD ideal,next . For BG current ≥ BG upper target , the model for the rate of descent will hold that the ideal ROD ideal , next is a bounded exponential function of the FEBG. For BG current ≥ BG upper target , the model relating insulin infusion rate IR next to ROD ideal,next remains linear, but IR next will be a bounded decaying exponential function of BG current . At hyperglycemic BG values, IR = MR + CR will approach a maximum value asymptotically or, in other words, CR will approach a maximum value, CR max .
Management of Euglycemic Ascent to Target
The algorithm does not directly seek to attain BG true target during euglycemic ascent to target, but rather to restrain the ROA in proportion to both ROA max and the proximity of BG current to target. For BG < BG true target , the linear function (BG current , ROA ideal,next ) giving the ideal rate of ascent of BG for the next iteration (ROA ideal,next ) is defined by the points: 
Management of Hyperglycemia
The algorithm does not directly seek to attain BG true target during descent except by assigning ROD ideal,next conservatively after each hyperglycemic iteration. 
Prevention of Hypoglycemia
Blood glucose test times under the algorithm occur on the hour, every 1 or 2 hours. Based on changes of carbohydrate exposure, insulin in TPN, or CVVHD, between protocol BG test times nursing staff may recognize that an indication for downward reassignment of MR has occurred. Without necessity for retesting BG, the MR is reassigned immediately to 50% of MR initial , according to the hypoglycemia risk-adjusted MR rate rules outlined in Appendix 1, and IR is recalculated dependent on the new MR. The insulin rate adjustment should not be delayed until the next scheduled BG test time. After such adjustment, the next BG test time occurs on the hour at the next hour, as described later and in Appendix 2.
Management of Hypoglycemia and Interpretation of Algorithm Rules after Hypoglycemia
Hypoglycemia may be recognized at algorithm test times or may be suspected and detected because of patient manifestations occurring between algorithm test times. The time of hypoglycemia occurring between algorithm test times is assigned, under the algorithm, to the nearest hour on the hour. Institutional protocols are used for the treatment of BG <70 mg/dl. An acceptable protocol for treatment of BG <70 mg/dl is administration of a bolus infusion of 12.5 grams dextrose given as 25 cc of 50% dextrose in water, followed by repeat BG testing after 10 minutes. Retreatment and further retesting occur as often as required by symptoms, by manifestations, or by evidence of relapse.
If BG previous had been above BG upper target , then to compute ROD previous , a value of BG current <70 mg/dl at an algorithm test time is accepted as unmodified data. For all computational purposes other than determination of ROD previous , detection of BG current <70 mg/dl results in reassignment of the value of BG current to equal 70 mg/dl. Immediate rebound BG elevations above 70 mg/dl may occur after treatment of hypoglycemia. Any interval BG values collected for safety, obtained by retesting after the treatment of hypoglycemia but before the next algorithm hourly test time, are not used to determine MR or IR; BG current , reassigned to be 70 mg/dl, is used to mandate that IR = IR @BG70 for the next hour or the remaining fraction of the hour. After treatment of hypoglycemia, the next BG value eligible for use in the determination of IR next is the BG obtained at the subsequent hourly test time under the algorithm. IR @BG70 is infused from the real time at which hypoglycemia occurred until completion of the hour following the algorithm time to which the hypoglycemic event was assigned. At that time, the tentative MR equals 80% of the last MR carried forward, and rules for assigning MR are applied (Appendix 1).
Real Time and Algorithm Times: Practical Programming Suggestions
Algorithm times assigned to BG results are restricted so as to occur on the hour. To determine the time of BG previous , BG current , ∆ time previous , and ROD previous or to determine ∆ time next for the future, the real times of BG tests are rounded to the nearest algorithm time. For BG tests occurring exactly on the half-hour, the assigned algorithm time is the real test time rounded to the next hour.
If hypoglycemia occurs or if there is recognition between algorithm test times that a criterion for hypoglycemia risk-adjusted MR reassignment has occurred, then between algorithm times, by opening a "returning screen," a nurse should use the algorithm to request a reassignment of IR (see Appendix 1). If a nurse opens the "returning screen" to request a reassignment of IR between algorithm times without entering a new value for BG current , the start time for the new IR must be identified with an algorithm time. The time of initiation of the new IR is stated to be the nearest algorithm time, on the hour; continuing from this time, the next test time next is given according to the rules of the algorithm, using ∆ time next = 1 hour.
If a BG test, done between algorithm times, is used in the "returning screen" to request a reassignment of IR and if the nearest algorithm time was the previous hour on the hour, then the value of the new BG replaces the previously determined BG value that had been assigned to correspond to an algorithm time at the previous hour on the hour. If a BG test done between algorithm times is used in the "returning screen" to request a reassignment of IR and if the nearest algorithm time is the next hour on the hour, then the new BG becomes the BG that corresponds to the next algorithm time. The availability of this value eliminates the need to redetermine the BG at the next hour on the hour. Although starting in real time between algorithm times, the newly assigned IR will be understood within the algorithm to have started at the algorithm time that was assigned to the newly determined BG.
At the beginning of the next iteration, a computation of MR csne may have to be made. If so, the ROD previous is calculated by taking the irregularly timed BG as BG previous , associated with a previous algorithm time rather than real time, and by taking the current BG as BG current , the ∆ time as 1 hour, and the start time for IR previous as the previous algorithm time.
Segmented Asymmetric Nearly Sigmoidal Curve
At a given MR, when the entire domain of BG is considered, an asymmetric nearly sigmoidal function IR of BG will be created, segmented into parts below BG true target (an exponential relationship between IR next and BG current ), between BG true target and BG upper target (a constant relationship), and above BG upper target (a bounded decaying exponential relationship) (Figure 4) . The effect is that the equation for IR next as a function of MR and BG current will resemble an asymmetric doubly sigmoidal curve.
Application to Populations
For a given set of parameter values, a family of iso-MR equations giving IR as a function of BG is created. Figure 4A) . For a patient belonging to a different population, the family of curves may be shifted to the right or shifted up or down ( Figure 4B ). For purposes of comparing two populations, at given MR the function is shown for a patient who may be a surgical ICU patient and another who may be under treatment for ketoacidosis ( Figure 4C ).
Hypotheses about Algorithm Parameters Discoverable in Nature
Methods are suggested for the verification of estimated values of three algorithm parameters ( Table 3) . By definition, MR true is the mean IR on stable intervals. MR true reflects actual insulin delivery on intervals of stability close to target range BG control and thus estimates the biologic value of MR. It is hypothesized that MR csne , computed during the correction of hyperglycemia, will estimate MR true .
and ROD previous can be captured over the antecedent hyperglycemic 4 hours prior to entry to each qualifying stable interval. Population averages, dependent in part on the level of carbohydrate exposure, then can be determined for the G-per-DIEM parameter. There is reason to believe that the G-per-DIEM parameter at a given level of carbohydrate exposure may be a higher number for type 1 diabetes than for stress hyperglycemia or type 2 diabetes. 48 The future possibility of a real-time determination of patient values for G-per-DIEM during the individual course of treatment is not discounted.
Hypothesis about ROA max
The ROA max is defined at BG = 70 mg/dl, equaling the observed ROA during a subsequent iteration in which IR = IR @BG70 . At euglycemic BG values >70 mg/dl, it is likely to be infrequent that the multiple necessary conditions can be met for the computation of ROA max . The equations would be as follow: 
Hypothesis about G-per-DIEM
The G-per-DIEM will be assigned arbitrarily as 1800 mg/dl during initial trialing. The hypothesis holds that replacement of the default G-per-DIEM with the estimated population average value of G-per-DIEM will improve the ability of MR csne to estimate MR true . It is doubtful whether ROA max can be estimated by either of the previously suggested methods, but the possibility will be studied.
The model holds that replacement of the default ROA max with the discovered population average value of ROA max will improve the ability to predict time to target during the euglycemic ascent of BG.
User-Assigned Parameters
The following population types may prove to have differing parameters: adult surgical ICU, standard adult not critically ill, children <18 years, diabetic ketoacidosis, diabetic ketoacidosis in children <18 years, hyperglycemic hyperosmolar state, chronic renal failure, and patients having BG <50 within 24 hours prior to initiation of the algorithm or having a perceived high risk for hypoglycemia (Appendix 3). 
Discussion
Feasibility Studies
Limitations of the study include the fact that steady-state conditions of insulin infusion and BG response were not met between BG samples. Because the mean IR on
• stable intervals was taken to be an approximation of the true MR, it is necessary to explain why the MR csne systematically overestimated the mean IR on stable intervals. One possibility is that an imperfect estimate of maintenance requirements may be provided by the formula for MR csne . Another possibility is that, on average, less than true maintenance requirements may have been delivered during stable intervals. A third possibility is that during stable intervals, ongoing improvement of acute glucotoxicity may have been occurring. A fourth possibility is that for the trauma patient population, the value "1800 mg/dl" used in the algorithm may be inappropriate to the calculation of the insulin sensitivity factor. A fifth possibility is that despite rounding of times for purposes of charting, actual test times and infusion rate change times may not have occurred on the hour punctually.
The benefits to be anticipated are a reduction in oscillations of the BG, safety with respect to hypoglycemia, and attainment of targets that may be specified to differ according to population. The ability of an algorithm to deliver these benefits could not be evaluated without conducting patient trials. The principal limitation of the study is that the response to the algorithm cannot be predicted by a hypothetical application to successive time points within a treatment course that was, in fact, conducted under the rules of the predecessor protocol.
Proposal for Computerized Algorithm "I, Pancreas"
A programmable algorithm is described for intravenous insulin infusion. The new algorithm, as well as its predecessor protocol of proven safety, 41 employ similar rules for the assignment of IR, dependent on discovery of an approximate MR and use of an exponential rule for euglycemic ascent. Whereas the predecessor protocol relies on cumbersome column-change rules to select the best of six possible values for MR, the new algorithm calculates an intermediary continuous variable, the MR csne . Prior to attainment of normoglycemia, although the feasibility study suggests that the new algorithm would assign slightly higher IR values at isolated historical time points, the respective IR values under the old protocol and new algorithm are tightly correlated. Although the MR csne upon entry to a stable interval in the feasibility study is slightly higher than the estimated hourly maintenance insulin requirement (historical mean IR on the ensuing stable interval), the two values are tightly correlated.
In contrast to the column-based method of selection from six possible values for MR, calculation of MR csne by the new algorithm allows for a continuous spectrum of values for MR, and each hyperglycemic iteration provides an opportunity for the adjustment of MR. In future applications we will replace the linear rule for the correction of hyperglycemia, used in the feasibility studies, with a bounded decaying exponential rule. We believe that the method of correction of hyperglycemia, as well as the management of euglycemia, determine the safety of an algorithm with respect to hypoglycemia prevention. The exponential rule for the management of euglycemia, an important feature of the predecessor protocol, will be preserved in the new algorithm.
Future Directions
Using data from stable intervals for calculation, future work will attempt to determine special parameter values in a population-dependent manner. To optimize protection against hypoglycemia, concepts of the rate of delivery of the hypoglycemic action of insulin in units per hour (HR) and the rate of delivery of carbohydrates in grams per hour (C6R) in the future will be incorporated into the assignment of IR next . Figure 4 uses the simplifying assumption that the pharmacodynamic delay for intravenous insulin is negligible, i.e., that the onset and cessation time for HR is zero, or HR = IR. Future algorithm revisions may invoke HR. Administration of a priming bolus of insulin will be prohibited. At the time of algorithm initiation, the use of HR to calculate IR will account for the lack of insulin during the preceding hour. If computations indicate a need to neutralize the hypoglycemic action of insulin already delivered, the algorithm will calculate a "negative" rate of insulin delivery for IR next , and the response recommended under the algorithm will be an infusion of dextrose. Otherwise, the pharmacodynamic delay of insulin already administered will be factored into the computation of MR csne and IR next . At this time, because a model for HR is not in place, 49-51 the simplest assumption is used, HR = IR.
Adaptation to a change of carbohydrate exposure under the present design is either reactive or arbitrary. In order to match carbohydrate exposure, C6R, together with a matching rule for the discovery of insulin-tocarbohydrate requirements, may be incorporated into future versions of the algorithm.
For a given value of MR, the relationship between IR next and BG current is presently based on models using intermediary variables, the FRROA ideal,next and ROD ideal,next , which in turn depend on the distance of BG current from target BG. The segmented curves are defined by upper where IR is a function of the intermediary variables MR, FRROA ideal, next , and ROD ideal,next , and where ROD ideal,next at BG critical high is specified as an algorithm parameter.
A long-range goal is to describe the IR-defining second step of the algorithm as a continuous, strictly increasing, differentiable function on the entire MR and BG domain, giving IR next as a function of MR and BG current without using other intermediary variables. The two asymptotes and the MR will be preserved as algorithm parameters, and the shaping points will be retained, giving IR @BG70 and IR @BG critical high at BG 70 mg/dl and at BG critical high , respectively. There will be three inflection points, assigned such that BG target minus corresponds to BG true target and that BG target plus corresponds to BG upper target :
(BG target minus , MR minus ) (BG mid target , MR) (BG target plus , MR plus )
Although the exact values need to be determined, initial pilot studies on the behavior of the segmented curve will give evidence on the appropriateness of choices that may be made for asymptotes, inflection points, and shaping points. The appearance will be that of an asymmetric doubly sigmoidal curve.
Conclusion
In summary, an algorithm is described that seeks patient MR and assigns commensurate IR. As a replacement for column-change rules of paper protocols, the electronic version of our MR algorithm will add computation of MR csne to the design of those predecessor algorithms. With the intent of reducing risk for hypoglycemia, the exponential rule of a predecessor protocol for the management of euglycemia is preserved. Computerization is expected to facilitate adaptation of the algorithm to various patient populations by assigning a populationdependent panel of default parameter values in response to user input. Computerization will reduce conceptual burden and errors of column-change rules. It is possible that data collected during use of the algorithm will permit investigators to refine population averages for algorithm parameters and even to propose the real-time revision of parameters during the treatment course of an individual patient. The design features define a method for specifying glycemic targets that are allowed to differ according to patient condition. It is hoped that these effects will translate into the advantages of a reduction of glycemic variability and of hypoglycemia and will enable the algorithm to perform with flexibility across populations. If BG previous ≥ BG true target , then the following apply:
If rehydration time has not elapsed, tentative MR = MR initial , unless BG current < BG lower target , in which case tentative MR = 80% of MR initial Otherwise, tentative MR = MR csne If BG previous < BG true target , or if BG is unavailable at the time of last change of IR, then the last MR is carried forward to become the tentative MR, unless BG current < BG lower target , in which case tentative MR = 80% of last MR carried forward.
Maintenance rate for subsequent iterations:
The MR for any subsequent iteration is the minimum of the tentative MR, the TPN-adjusted tentative MR, and the hypoglycemia risk-adjusted tentative MR, where
Tentative MR is defined as described earlier TPN-adjusted tentative MR is defined as follows: if insulin additive to TPN will be increased, then TPN-adjusted tentative MR = tentative MR -(24-hr increment of insulin added to TPN)/24 h Hypoglycemia risk-adjusted MR is defined as follows: if tube feed interruption, ≥ 50% reduction of dextrosecontaining maintenance fluid infusion rate (from rate at least 40 cc/h of 5% dextrose-containing maintenance fluids, 20 cc/h of 10% dextrose-containing maintenance fluids, or 10 cc/h of TPN or equivalent), or interruption of CVVHD will occur within the next iteration or has occurred at the present time, then hypoglycemia risk-adjusted tentative MR = 50% of MR initial .
a The MR assignment rules permit estimation of MR during hyperglycemia and apply arbitrary MR reassignment rules during euglycemia.
Criteria for MR revision after pressor revision have not been developed. However, if BG previous < BG true target , then abrupt interruption of pressor support may also require arbitrary MR revision. The program for the algorithm will retain memory of previous data input and output.
The interface with the user will solicit confirmation of IR previous and other appropriate input. MR reassignment also occurs if nursing staff recognize hypoglycemic manifestations or recognize that criteria for hypoglycemia risk-adjusted MR reassignment have occurred between algorithm test times (for details, see text).
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